Companies with patents are 10.2x more likely to secure early-stage funding. Most founders use that stat to attract equity investors. The smarter move in 2026 is IP funding: raising $2M to $20M against your patent portfolio without giving up a single share of ownership.
Hayat Amin argues that IP funding is the most underused capital structure in tech because founders still treat patents as legal shields, not financial instruments. When Western Technology Investment and Horizon Technology Finance started folding patent schedules into their underwriting models, the economics changed. Lenders now ask for your IP portfolio before your financial model. This is the guide to what IP funding actually is, who qualifies, and how to position your portfolio to access it.
What Is IP Funding?
IP funding is any capital raise where intellectual property assets serve as the primary or supplementary collateral backing the loan. The founder gives up zero ownership. The lender gets a security interest in a defined, valued asset: granted patents, trade secrets, or proprietary data. Interest rates drop compared to unsecured debt because the collateral reduces lender risk.
Three structures dominate the 2026 market. Patent-backed loans use granted patents as direct collateral, typically at 20-40% loan-to-value ratios, with interest rates running 8-15% APR. IP-backed venture debt folds IP valuation into underwriting alongside revenue and ARR metrics, extending the credit facility by 15-30% beyond what revenue alone supports. Royalty-advance financing lets patent holders borrow against projected licensing income from executed or anticipated license agreements.
The structural force behind IP funding is simple math. Intangible assets now represent over 90% of S&P 500 market capitalization, up from 17% in 1975. Lenders ignored that shift for decades. Insurance-wrapped IP loans from firms like Aon and Marsh now de-risk patent collateral for lenders who previously refused to touch it. The result: IP funding moved from exotic to accessible in under two years.
Why IP Funding Went Mainstream in 2026
IP funding went mainstream because three barriers fell in the same 18-month window: credible IP valuation tools became accessible, insurance carriers created wraps that backstop patent collateral, and default data proved IP-backed borrowers are safer bets than the general lending pool.
The default data is what changed lender behavior. A EUIPO study covering hundreds of billions in IP-backed lending found that companies with registered intellectual property show 38% lower probability of default. Patent holders default at 6% versus 16% for the total sample. Those numbers made IP-backed loans actuarially attractive overnight.
Beyond Elevation's advisory team watched this shift in real time. In Q4 2025, two client companies closed IP-backed credit facilities that their banks had rejected 12 months earlier. The patents were the same. The lender's risk model was different.
Western Technology Investment and Horizon Technology Finance now formally include IP valuation in their underwriting. They request the patent schedule before the financial model. Hayat Amin says founders who show up without a documented IP valuation are losing meetings they should be winning. For founders already exploring patent-backed borrowing, our venture debt IP collateral playbook covers the exact deal mechanics.
The Four Types of IP Funding Available in 2026
Four distinct IP funding structures are active in the 2026 market. Each fits a different stage, portfolio size, and capital need. Picking the wrong structure wastes months of diligence on a deal that was never going to close.
Patent-backed loans. A lender takes a security interest in one or more granted patents and advances capital at 20-40% of the appraised portfolio value. Typical deal size: $2M to $20M. Interest rates run 8-15% APR. No warrants, no equity, no board seats. BlueIron and Inngot are the specialist originators. Hayat Amin's rule for founders considering this route: if you have five or more granted patents with at least seven years of remaining life and any evidence of licensing demand, you likely qualify. Most founders who assume they do not qualify are wrong.
IP-backed venture debt. This is the hybrid model. Lenders like WTI and Horizon use IP valuation as an underwriting multiplier alongside revenue metrics. The IP does not serve as standalone collateral. A strong patent portfolio extends the credit facility by 15-30% beyond what revenue alone supports. For a company doing $5M ARR, that difference is $750K to $1.5M in additional non-dilutive capital.
Royalty-advance financing. Patent holders who already license their IP can borrow against projected royalty streams. The lender advances 50-70% of the next 24-36 months of projected licensing income. This works for companies with at least one executed license agreement generating recurring revenue. The patent licensing revenue model guide covers how to build a licensable portfolio that unlocks this option.
IP sale-leaseback. A company sells its patent portfolio to an IP holding entity, receives immediate capital, and licenses the patents back under a long-term exclusive agreement. The company keeps operational use of the IP while unlocking its balance-sheet value. This structure is common in real estate and is now entering the IP market through entities structured in Jersey, Luxembourg, and the Isle of Man.
Does Your Patent Portfolio Qualify for IP Funding?
Your patent portfolio qualifies for IP funding if it passes four conditions. Hayat Amin calls this the IP Funding Readiness Test, and lenders apply these filters before they request a formal valuation.
Condition 1: Granted, not pending. Provisional and pending applications carry zero collateral value for IP funding. Lenders require at least one granted patent in a major jurisdiction (US, EU, UK, Japan, or China). More grants equal more collateral and better terms.
Condition 2: Remaining useful life exceeds seven years. A patent with three years left is a depreciating asset. Lenders want a runway that exceeds the loan term by at least 2x. If your earliest core patent expires in 2030, the window for IP funding is closing fast.
Condition 3: Broad claims that map to commercial use. Patents with narrow, design-around-friendly claims do not attract lender interest. The claims must cover technology that identifiable companies use in commercial products. Hayat Amin reminds founders that a patent nobody infringes is a patent nobody will lend against.
Condition 4: Evidence of licensing value. This does not require an executed license. A third-party IP valuation, a claim chart mapping competitors' products to your patent claims, or a credible licensing pipeline proposal gives lenders the market signal they need. Beyond Elevation runs this exact assessment as the first step in every IP-backed financing engagement.
If your portfolio clears all four conditions, you are in the top 15% of patent holders eligible for IP funding. Most founders fail on condition 3 because their patent attorney filed narrow claims optimized for prosecution speed, not commercial leverage.
How Much Can You Raise Through IP Funding?
The amount you raise through IP funding depends on portfolio appraised value, loan-to-value ratio, and deal structure. These are the 2026 benchmarks founders should use to set expectations before the first lender meeting.
For patent-backed loans, expect 20-40% LTV on appraised portfolio value. A portfolio valued at $10M supports a $2M to $4M credit facility. For IP-backed venture debt, the IP valuation adds 15-30% to what revenue alone would support. A $5M ARR company with a strong patent portfolio accesses $750K to $1.5M more than a comparable company without IP. For royalty-advance financing, the advance runs 50-70% of 24-36 months of projected licensing income.
These numbers are closing in the market right now. Insurance-wrapped IP loans from $2M to $20M funded every quarter of 2025 and 2026. The economics beat mezzanine debt (15-25% APR) and venture debt without IP backing (which typically requires warrants worth 1-3% of equity). For founders who hold patents, IP funding is the cheapest non-dilutive capital available in 2026.
How Should Founders Prepare for an IP Funding Raise?
Founders who want to access IP funding should start preparing six months before they need the capital. Lenders run the same diligence on IP portfolios that acquirers use in M&A. Walking in unprepared burns the relationship.
Start with an independent IP audit. Hayat Amin's team at Beyond Elevation runs a 6-step IP audit that maps every patent to commercial use, identifies valuation drivers, and flags weaknesses before a lender finds them. An independent audit adds 15-20% to your valuation multiple and compresses the lender's diligence timeline from weeks to days.
Next, get a formal IP valuation from a credible third party. Lenders will not accept a self-assessed number. The valuation should use at least two of the three standard methods (cost, market, income) and provide a defensible range.
Finally, prepare claim charts showing how your patents map to products or services used by identifiable companies. This is the evidence of licensing demand that separates a dormant portfolio from a lendable one. You do not need executed licenses. You need credible evidence that the IP has commercial value beyond your own products.
Your patents are financial instruments. The question is whether you can prove it to the people writing the checks. Talk to Beyond Elevation and we will build the valuation story that turns your portfolio into capital.
FAQ
What is the difference between IP funding and venture debt?
IP funding uses intellectual property as primary collateral. Venture debt uses revenue, ARR, and cash flow as underwriting metrics, often with warrants attached. IP-backed venture debt is the hybrid: lenders fold IP valuation into the underwriting model alongside revenue, extending the credit facility without requiring equity conversion.
Can startups with only provisional patents get IP funding?
No. Provisional patent applications carry zero collateral value for IP-backed loans. Lenders require at least one granted patent in a major jurisdiction. Founders who are pre-grant should accelerate prosecution through track-one prioritized examination at the USPTO, which cuts grant timelines from 24 months to 6-12 months.
How long does an IP funding deal take to close?
Most IP-backed loan deals close in 60-90 days from initial engagement. The timeline depends on portfolio complexity, valuation turnaround, and lender diligence depth. Founders who arrive with a current IP audit and third-party valuation compress the process to 30-45 days.
What happens to my patents if I default on an IP-backed loan?
The lender holds a security interest in your patent portfolio. On default, the lender can foreclose on the IP assets, typically through a UCC Article 9 sale. Insurance wraps from specialty IP insurers protect the lender and can limit default severity for the borrower.
Is IP funding available outside the United States?
Yes. IP-backed lending is active in the UK (British Business Bank programs), the EU (EUIPO-backed pilots), Hong Kong (the IP-Finance Sandbox launched in 2026), and Singapore. The Isle of Man's Data Asset Foundation structure also enables IP-adjacent funding against registered datasets.